ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.

D Ross Camidge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.